Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Monday, June 22, 2015

Researchers Suggest Short Transition Period Between Natalizumab and Fingolimod Therapies to Control RRMS Disease Activity


Researchers Suggest Short Transition Period Between Natalizumab and Fingolimod Therapies to Control RRMS Disease Activity    An international team led by researchers at the University Hospital Basel in Switzerland revealed that a short period of 8 to 12 weeks is the optimal timing to be considered when patients with relapsing-remitting multiple sclerosis (RRMS) are switched fromnatalizumab to fingolimod therapy. The study was recently published in the journalNeurology and is entitled “Switching from natalizumab to fingolimod, A randomized, placebo-controlled study in RRMS.


~~~~~~~~~~~~~~~~~~~
 Keep CURRENT with MS Views and NewsOPT-IN here


.
.


No comments: